Why this undervalued ASX 200 biotech share is worth a closer look

Although global economic sentiment remains grim, here's why I think PolyNovo Ltd (ASX: PNV) is a buy if the markets continue to fall.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The coronavirus pandemic and the oil trade-war between Saudi Arabia and Russia have wreaked havoc across global markets over the last four weeks shedding over 25% from both the S&P/ASX 200 Index (ASX: XJO) and the Dow Jones Industrial Average.

Among those heavily affected is Australian biotech company PolyNovo Ltd (ASX: PNV), which has seen its share price fall a staggering 46% from its 52-week high of $3.28 to $1.78 at Friday's close.

Although global economic sentiment remains grim, here's why I think PolyNovo is a buy if the markets continue to fall.

Coronavirus: Little impact on PolyNovo

On 11 March 2020, PolyNovo released an announcement to ease investors minds in regards to the impact of coronavirus on the company's operations.

On the supply side, PolyNovo does not source any raw materials from China and has multiple supplier redundancies built into their supply chain. Additionally, the company has enough finished product on shelves to meet anticipated sales for a significant time period with enough material inventory for the remainder of the year. As a result, the company currently does not anticipate any significant supply chain disruptions in its operations throughout Australia, New Zealand, the United States, and the United Kingdom.

On the demand side, PolyNovo does not sell into China. The main uses of PolyNovo's flagship product NovoSorb is in emergency, traumatic, or extensive surgery applications. These surgeries are anticipated to continue regardless of the coronavirus as these procedures are generally not elective surgeries. Therefore, the nature of NovoSorb allows product demand to remain predictable going forward.

What is NovoSorb?

PolyNovo has used a base polymer created by CSIRO to create NovoSorb – a polymer with foaming processes and new formulations specifically for medical devices. These polymers work by supporting different functions of the body and then harmlessly biodegrading through absorption or excretion.

The main application of NovoSorb is NovoSorb Biodegradable Temporising Matrix (BTM), a man-made synthetic polymer designed to help surgeons treat traumatic wounds. NovoSorb BTM is used to temporarily close wounds and aid the body in generating new tissue.

NovoSorb has achieved regulatory approval in a substantial number of countries, with 5 additional approvals in process. Commercial revenues have skyrocketed over the last three years with H1 2020 sales amounting to $8.45 million – up 129% from the same period last year. These revenues are expected to continue growing with 2020 sales anticipated to comfortably double 2019 figures.

In addition to scaling NovoSorb globally, PolyNovo also has a strong development pipeline with expansions into hernia devices, breast augmentation/reconstruction, drug elution and beta cell technologies. These developments are on-track with manufacturing and trials to be completed by the end of the year with a total market value estimated at over $6 billion.

Foolish takeaway

Investing in a time of huge volatility is always risky. However, markets falling provide a fantastic opportunity for long-term growth in great companies. With the impact of coronavirus on PolyNovo's operations minimal, PolyNovo is a great company to invest in long-term at these prices.

Motley Fool contributor Jordan Liu has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why this top broker expects CSL shares to surge 26%

A leading broker foresees a big rebound ahead for CSL shares. But why?

Read more »

Man jumps for joy in front of a background of a rising stocks graphic.
Healthcare Shares

Guess which ASX All Ords stock is jumping on big US news

This small cap is catching the eye on Thursday. But why?

Read more »

three excited doctors with hands in the air
Healthcare Shares

Two ASX healthcare shares that could be set to double

This broker has buy recommendations on these two shares. 

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Telix shares jump 7% on big US news

Let's see what is getting investors excited on Wednesday.

Read more »

An older gentleman leans over his partner's shoulder as she looks at a tablet device while seated at a table.
Healthcare Shares

Macquarie tips 28% upside for this ASX healthcare stock

The broker expects big things from this New Zealand retirement village developer and operator.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

$10,000 invested in these ASX healthcare shares 5 years ago is now worth…

These healthcare stocks have brought big returns for investors 

Read more »

A man wearing a white coat and glasses is wide-mouthed in surprise.
Healthcare Shares

Guess which ASX 300 stock is crashing 55% today

What's going on with this stock? Let's see why investors are hitting the sell button.

Read more »

Woman serving customer in pharmacy.
Healthcare Shares

Up 132% in a year, are Sigma Healthcare shares still a good buy post the Chemist Warehouse merger?

After gaining 132% in 12 months, it too late to buy Sigma Healthcare shares today?

Read more »